Orphazyme (Denmark) Top Management
ORPHA Stock | DKK 950.00 39.80 4.02% |
Orphazyme employs about 2 people. The company is managed by 14 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 0.14 employees per reported executive. Evaluation of Orphazyme's management performance can provide insight into the firm performance.
Anders Vadsholt CEO Interim Chief Executive Officer, Chief Financial Officer |
Kim Stratton CEO Chief Executive Officer |
Orphazyme |
Orphazyme Management Team Effectiveness
The company has return on total asset (ROA) of (1.334) % which means that it has lost $1.334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.8658) %, meaning that it generated substantial loss on money invested by shareholders. Orphazyme's management efficiency ratios could be used to measure how well Orphazyme manages its routine affairs as well as how well it operates its assets and liabilities.Orphazyme Workforce Comparison
Orphazyme AS is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 7,213. Orphazyme adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (2.76) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (15.38) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $15.38. Orphazyme AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Orphazyme AS Price Series Summation is a cross summation of Orphazyme price series and its benchmark/peer.
Orphazyme Notable Stakeholders
An Orphazyme stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orphazyme often face trade-offs trying to please all of them. Orphazyme's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orphazyme's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Anders Vadsholt | Interim Chief Executive Officer, Chief Financial Officer | Profile | |
Kim Stratton | Chief Executive Officer | Profile | |
Georges Gemayel | Chairman of the Board | Profile | |
Bo Hansen | Deputy Chairman of the Board | Profile | |
Remi Droller | Director | Profile | |
Anders Hedegaard | Director | Profile | |
Catherine Moukheibir | Director | Profile | |
Sten Verland | Director | Profile | |
Martin Bonde | Director | Profile | |
Martijn Kleijwegt | Director | Profile | |
MBA MSc | CFO CEO | Profile | |
Jennifer McCann | I US | Profile | |
Thomas Blaettler | Chief Medical Officer | Profile | |
Thomas Jensen | Chief Scientific Officer | Profile |
About Orphazyme Management Performance
The success or failure of an entity such as Orphazyme AS often depends on how effective the management is. Orphazyme management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orphazyme management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orphazyme management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
Please note, the presentation of Orphazyme's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orphazyme's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Orphazyme's management manipulating its earnings.
Orphazyme Workforce Analysis
Traditionally, organizations such as Orphazyme use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orphazyme within its industry.Orphazyme Manpower Efficiency
Return on Orphazyme Manpower
Revenue Per Employee | 18.1M | |
Revenue Per Executive | 2.6M | |
Net Loss Per Employee | 313.3M | |
Net Loss Per Executive | 44.8M |
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |